Self-amplifying RNA (saRNA)

Revolutionizing Vaccine Development

Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development.

Benefits of saRNA
  • saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine
  • Manufacturing is cell-free, does not require a dedicated facility
  • saRNA vaccines often produce a higher immune response from a smaller dose when compared to mRNA based vaccines


Request a Sample of saRNA

Interested in a sample of saRNA? Use the link below to submit your request. If you have any other questions, please reach out to our client relations team for assisstance.


Request Sample

saRNA Inventory Products

Increase the duration and level of antigen expression for a better immune response using self-amplifying RNA technology. Aldevron offers a synthetic replicon design based on a single-stranded RNA alphavirus that expresses GFP / SEAP / LUC reporter enzyme. For research use only, easily measure the reporter gene expression in vivo to evaluate self-amplifying RNA and optimize delivery formulations in your application.

Note: saRNA products are classified by Aldevron under ECCN 1C353 on the Commerce Control List set forth in the US Export Administration Regulations (EAR), which is highly controlled for purposes of export outside the United States. If the product is requested to be shipped outside the US, an export license from US Dept. of Commerce’s Bureau of Industry and Security is required before the product may be shipped.

Pack Sizes

AldnLUC saRNA™

Related News

In the News: Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines

Aldevron, a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc. ("Ginkgo") today announced a...

In the News: Aldevron Adds Self-Amplifying RNA to its Product Portfolio

Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced today the...

Aldevron Adds DasherGFP mRNA to its Product Portfolio

FARGO, N.D. (February 12, 2019)—Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies to...

Related Blog Posts

TIDES TV: Tackling mRNA Manufacturing Challenges

Nate Spangler, Ph.D., Director of Innovation & Strategy at Aldevron discusses the challenges of manufacturing mRNA under the increased demand and...